Augustine Therapeutics has raised €78 million to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases. The proceeds from the financing will advance Augustine’s lead candidate, AGT-100216, through a Phase II proof-of-concept clinical trial in Charcot-Marie-Tooth and support significant pipeline expansion.  Jeito Capital, a global independent Private Equity fund, and Novo Holdings, new investors, co-led […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!